2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 528

Mxa As a Biomarker for Systemic Interferon Type I Activation in Primary Sjögren′s Syndrome
Abstract Number: 289

Mycophenolate Mofetil and Abatacept Combination Therapy in Refractory Pediatric Systemic Lupus Erythematosus Nephritis
Abstract Number: 340

Myeloid Deletion of SIRT1 Aggravates Inflammatory Arthritis Via Nuclear Factor-Kappab Activation in Animal Model of Rheumatoid Arthritis
Abstract Number: 1674

Myeloid Related Proteins Induce Muscle Derived Inflammatory Mediators in Juvenile Dermatomyositis
Abstract Number: 2070

Myeloid-Derived Suppressor Cells Accumulated in Spleens of Mice with Collagen-Induced Arthritis and Inhibited Immune Response of CD4⁺ T Cells
Abstract Number: 1738

Myocardial Dysfunction and Valvulopathy Worsens with Time in Patients with Antiphospholipid Syndrome: A 10-Year Follow-up Study
Abstract Number: 711

Myopathy Is a Poor Prognostic Feature in Systemic Sclerosis: Results From the Canadian Scleroderma Research Group
Abstract Number: 1672

Myosin Skews Effector Immune Cells of Scurfy Mice to Target Muscles in an Adoptive Transfer Model of Myositis
Abstract Number: 1675

Myositis Autoimmunity and Muscle Weakness Are Linked to TNF-Alpha Suppression of Micrornas-1, 133, and 206 in Myoblasts and Myocytes
Abstract Number: 217

Myositis-Associated Usual Interstitial Pneumonia Has Better Survival Than Idiopathic Pulmonary Fibrosis
Abstract Number: 2174

Natural History of Sjögren’s Syndrome Phenotypic Features in the Sjögren’s International Collaborative Clinical Alliance Registry
Abstract Number: 149

Natural Language Processing in the Evaluation of Gout Quality Indicators
Abstract Number: 1184

Negative Association Between Testosterone Levels and Risk of Future Rheumatoid Factor Negative Rheumatoid Arthritis in Men
Abstract Number: 784

Neutralization of Plasminogen Activator Inhibitor-1 Resolves Skin Fibrosis and Vascular Injury in a Murine Model of Human Scleroderma
Abstract Number: 1699

Neutropenia After Rituximab in Rheumatoid Arthritis and Other Autoimmune Diseases Is a Rare Events : Date From the Autoimmunity and Rituximab Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].